Pharmaceutical Approval Update.

Pharmaceutical Approval Update.
P T. 2019 May;44(5):251-254
Authors: Kaufman MB
Abstract
Cablivi (caplacizumab-yhdp) for acquired thrombotic thrombocytopenic purpura; Egaten (triclabendazole) for fascioliasis; and Spravato (esketamine) for treatment-resistant depression.
PMID: 31080332 [PubMed]

Source: P and T - May 15, 2019 Category: Drugs & Pharmacology Tags: P T Source Type: research